AbbVie Inc. (ABBV)
NYSE: ABBV · IEX Real-Time Price · USD
159.02
-8.27 (-4.94%)
Apr 26, 2024, 3:51 PM EDT - Market open
AbbVie Employees
AbbVie had 50,000 employees on January 31, 2024. The number of employees did not change compared to the previous year.
Employees
50,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,086,360
Profits / Employee
$97,260
Market Cap
282.50B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Jan 31, 2024 | 50,000 | 0 | - |
Jan 31, 2023 | 50,000 | 0 | - |
Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
Jan 31, 2020 | 30,000 | 0 | - |
Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
Jan 31, 2013 | 21,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ABBV News
- 7 hours ago - AbbVie's Q1 earnings beat expectations as arthritis drug boosts growth - Invezz
- 7 hours ago - AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Fall - Barrons
- 7 hours ago - AbbVie lifts profit forecast after Skyrizi sales beat expectations - Reuters
- 7 hours ago - AbbVie's first-quarter results top expectations as arthritis drugs fuel growth - Market Watch
- 7 hours ago - AbbVie Reports First-Quarter 2024 Financial Results - PRNewsWire
- 1 day ago - AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study - Reuters
- 1 day ago - New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study - PRNewsWire
- 3 days ago - Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands - PRNewsWire